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OBJECTIVES We sought to determine the extent to which the capability of a hospital to perform invasive
cardiovascular procedures influences treatment and outcome of patients admitted with acute
myocardial infarction (AMI).
BACKGROUND Patients with AMI are usually transported to the closest hospital. However, relatively few
hospitals have the capability for immediate coronary arteriography, percutaneous transluminal
coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG), should these
interventions be needed.
METHODS The 1,506 hospitals participating in the National Registry of Myocardial Infarction 2 were
classified according to their highest level of invasive capability: 1) none (noninvasive, 28.1%);
2) coronary arteriography (cath-capable, 25.2%); 3) coronary angioplasty (PTCA-capable,
7.4%); and 4) bypass surgery (CABG-capable, 39.2%). Treatment and in-hospital outcomes
were assessed for 305,812 patients admitted from June 1994 through October 1996.
Follow-up through 90 days was ascertained in a subset of 30,402 patients enrolled
simultaneously in both the National Registry of Myocardial Infarction (NRMI) 2 and the
Cooperative Cardiovascular Project (CCP).
RESULTS The proportion of patients receiving initial reperfusion intervention was only slightly higher
at the more invasive hospitals (noninvasive 32.5%, cath-capable 31.2%, PTCA-capable 32.9%
and CABG-capable 35.9%, p , 0.001 by chi-square statistic). Among thrombolytic
recipients, median door-to-drug time interval differed little among hospital types and ranged
from 42 to 45 minutes. At cath-capable, PTCA-capable and CABG-capable hospitals,
coronary arteriography was performed in 32.9%, 37.4% and 64.9%, respectively, and PTCA
in 0.0%, 5.1% and 31.4%, both p , 0.001 by chi-square statistic. The proportion of patients
transferred out to other facilities was 51.0%, 42.2%, 39.9% and 4.4% (p , 0.0001) among
noninvasive, cath-capable, PTCA-capable and CABG-capable hospitals, respectively.
Among patients in the combined NRMI and CCP data set, mortality at 90 days
postinfarction was similar among patients initially admitted to each of the four hospital types.
CONCLUSIONS Although patients with AMI admitted to hospitals without invasive cardiac facilities have a
high likelihood of subsequent transfer to other facilities, their likelihood of receiving a
reperfusion intervention at the first hospital, their door to thrombolytic drug intervals and
their 90-day survival rates are similar to those of patients initially admitted to more invasively
equipped hospitals. These data suggest that a policy of initial treatment of myocardial
infarction at the closest medical facility is appropriate medical practice. (J Am Coll Cardiol
2000;35:371–9) © 2000 by the American College of Cardiology
Over the past two decades, a spectrum of interventions has
evolved for the treatment of acute myocardial infarction
(AMI), ranging from simple coronary care unit observation
with thrombolytic therapy for eligible patients, to more
complex interventions like immediate cardiac catheteriza-
tion followed by percutaneous or surgical coronary revascu-
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larization. Although all acute care hospitals should be able
to provide immediate thrombolytic therapy, less than 20%
are equipped to perform immediate coronary arteriography,
and even fewer have capability for immediate percutaneous
transluminal coronary angioplasty (PTCA) or coronary
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artery bypass graft surgery (CABG), if needed (1). If the
outcome of myocardial infarction (MI) were superior in
hospitals with invasive facilities, there might be rationale for
the regionalization of acute infarct care, similar to that
currently employed for victims of severe trauma. This would
entail the immediate transport of all patients with AMI to
regional care centers, rather than to the closest hospital, as
is currently done.
The National Registry of Myocardial Infarction (NRMI)
is an ongoing U.S. registry of patients with AMI and
involves hospitals of all levels of invasive capability for
cardiac care. The purpose of this investigation was to
determine whether, among patients enrolled in NRMI,
outcome is significantly influenced by the ability of a
hospital to perform invasive cardiovascular diagnostic test-
ing and interventions on patients admitted with AMI.
METHODS
Data sources. The NRMI is a voluntary nationwide U.S.
registry whose purpose is to describe the characteristics of
patients admitted with AMI at participating hospitals, the
treatment interventions utilized and the in-hospital out-
comes. The second phase of the registry, NRMI 2, began in
1994 and involved 1,506 hospitals, or 26% of all acute-care
hospitals in the U.S. (2). The NRMI methodology has been
previously described in detail (3). Briefly, upon joining the
registry, participating hospitals are required to complete an
enrollment form characterizing their local facilities and
services. Data from consecutive patients with AMI are then
recorded onto two-page case report forms and forwarded
to a central data collection and tabulation center,
STATPROBE, Inc. (Lexington, Kentucky). Confidential
quarterly data reports are provided to participating hospitals,
summarizing the hospital’s local registry data in parallel
with data from its state, the nation and data from hospitals
of like size and invasive capabilities. Local registry data may
then be utilized to assess local quality of care of patients
with AMI, and national data summaries can be used to
assess registry-wide practice patterns. To ensure quality
control of registry data, local registry coordinators are
trained to complete the data collection forms utilizing a
standardized manual of instructions and definitions. Case
report forms must pass systematic range and internal con-
sistency checks at the central data collection center before
being entered into the national database. Participating
hospitals obtain approval for the registry data collection
process as dictated by local policy. All patients enrolled in
NRMI 2 from June 1994 through October 1996 were
included in this study, except for those transferred into the
registry hospitals from other institutions.
Because survival ascertainment in NRMI is limited to the
initial hospitalization, additional data on survival to 90 days
postentry were obtained in a subset of patients enrolled in
both the NRMI 2 and the national Cooperative Cardiovas-
cular Project (CCP), sponsored by the Health Care Financ-
ing Administration (HCFA).
Hospital types. Registry hospitals were stratified into four
mutually exclusive categories based on data furnished by the
hospitals when they joined the registry:
1) noninvasive: no capability to perform coronary arteriog-
raphy (cath), PTCA or CABG;
2) cath-capable: coronary arteriography could be per-
formed, but not PTCA or CABG;
3) PTCA-capable: coronary arteriography and PTCA
could be done, but not CABG;
4) CABG-capable: coronary arteriography, PTCA and
CABG could be performed.
Definitions. The study protocol defined AMI as 1) history
and presentation suggestive of MI accompanied by either
total creatine kinase or creatine kinase-MB $ twice upper
limit of normal for the hospital’s laboratory or ECG
evidence of MI, or, in the absence of the above, alternative
enzymatic, scintigraphic, echocardiographic or autopsy evi-
dence of MI, or 2) an International Classification of
Diseases, 9th revision, clinical modification, discharge di-
agnosis code for MI, 410.01 through 410.91.
Hospitals were classified as “urban” if they were located in
a county with at least one city having a population of
.50,000 or two cities with a combined population of
.50,000. Teaching hospitals were those that were members
of the Council of Teaching Hospitals. States were grouped
into the U.S. census regions as previously described (4).
Patients were classified as “not low risk” if there was
evidence of ST-segment elevation on their first 12-lead
ECG and one or more of the following: age $70 years,
history of prior MI, initial systolic blood pressure
,100 mm Hg and pulse .100 beats/min, evidence of heart
failure upon admission or anterior/septal infarct location.
Treatment intervals for administration of thrombolytic
therapy were defined according to the National Heart
Attack Alert Program as follows: “door” indicates the time
of patient presentation to the hospital; “data,” the time of
acquisition of the diagnostic ECG; “decision,” the time it
was decided to administer thrombolytic therapy; and “drug,”
the time thrombolytic therapy was initiated (5). Major
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
cath 5 coronary arteriography
CCP 5 Cooperative Cardiovascular Project
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NRMI 5 National Registry of Myocardial Infarction
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bleeding included hemorrhagic episodes, other than intra-
cranial bleeding, resulting in substantial hemodynamic com-
promise.
Statistical methodology. In comparing hospital categories,
basic proportions were compared using the chi-square test
(6). Means of continuous variables were compared using
one-way analysis of variance (7), and medians were com-
pared using a nonparametric test of medians available in
SAS 6.12 (NPAR1WAY procedure) (8). Multivariate lo-
gistic regression models were fit to identify independent
predictors of hospital mortality (9). These models were fit
using a forward stepwise procedure where the indicator of
hospital type was forced into the model at the first step. In
order to evaluate the potential effect of hospital type and
other important covariates on 90-day survival among pa-
tients in the NRMI-2 database, a subset of the data was
linked to the HCFA-sponsored CCP database. This subset
was comprised of 30,402 patients whose data were matched
using an iterative algorithm that has been validated and
described in detail elsewhere (10). Following the linkage of
these two related data sets, Cox regression models were used
to estimate the effect of hospital type and other covariates of
interest on 90-day survival. Hazard ratios were derived for
each variable in these models, and 95% confidence limits
were fit around the point estimates of the hazard ratios.
Analyses were performed using a commercially available
statistical package (SAS 6.12, SAS Institute, Cary, North
Carolina). This report is based on data processed by the
central data collection center as of October 31, 1996.
RESULTS
Hospital characteristics. Among the 1,506 participating
registry hospitals, 423 (28.1%) were classified as noninva-
sive, 380 (25.2%) as cath-capable, 112 (7.4%) as PTCA-
capable and 591 (39.2%) as CABG-capable (Fig. 1). The
numbers of staffed beds in the four hospital types were
133 6 4, 215 6 5, 211 6 11 and 380 6 8 (mean 6 standard
error of the mean), respectively (p , 0.001). The propor-
tions with urban location were 58%, 75%, 84% and 95%,
respectively (p , 0.001), and the proportions that were
classified as teaching hospitals were 0.2%, 2.9%, 8.9% and
21.4%, respectively (all p , 0.001). In the South Atlantic
census region, cath-capable hospitals were most prevalent
(37%), and in the New England and Mid-Atlantic regions,
noninvasive hospitals predominated (prevalence 45% and
47%, respectively). In the six remaining U.S. census regions,
CABG-capable hospitals were the most common type with
prevalence ranging from 40% to 68%.
Patient characteristics. Among the 305,812 patients sat-
isfying the study criteria, 57,252 (18.7%) were enrolled at
noninvasive hospitals, 76,956 (25.2%) at cath-capable hos-
pitals, 24,251 (8.0%) at PTCA-capable hospitals and
147,153 (48.1%) at CABG-capable hospitals. Although
minor differences in clinical characteristics were observed
among patients enrolled at different types of hospitals
(Table 1), none was of sufficient magnitude to appear
clinically significant. Due to the large number of patients in
each group, achievement of statistical significance did not
necessarily imply clinical significance for the variables
shown in Table 1 or in the other tables.
Treatment. Among the four hospital types, the proportion
of patients receiving an initial reperfusion intervention
varied only minimally—from 31.2% in cath-capable hospi-
tals to 35.9% in CABG-capable hospitals (Table 2). When
reperfusion therapy was employed, it was always intravenous
lytic therapy in patients enrolled at noninvasive hospitals
(Fig. 2) and predominantly intravenous lytic therapy at the
other types of hospitals. At cath-capable hospitals 0.3% of
reperfusion attempted was by intracoronary (IC) lytic ther-
apy. At PTCA-capable hospitals, 10.2% of reperfusion
attempted was by primary PTCA and 0.5% by IC lytic
therapy. At CABG-capable hospitals, 34.2% of reperfusions
attempted were by primary PTCA, 1.0% by IC lytic therapy
and 3.0% by immediate CABG. Reperfusion attempted by
primary PTCA was significantly more common at CABG-
capable hospitals than at PTCA-capable hospitals (34.2%
vs. 10.2%, p , 0.001).
The physician ordering lytic therapy, when it was em-
ployed, was much less likely to be a primary care physician
and much more likely to be either an emergency department
physician or a cardiologist at the three invasive categories of
hospital (Table 2). The median thrombolytic door-to-drug
time was 0.72 hours (43 min) and did not differ substantially
among patients enrolled at the four different hospital cate-
gories. Among patients undergoing direct angioplasty, the
median door-to-balloon time was 2.2 hours.
The likelihood of obtaining a consultation before
initiating lytic therapy increased progressively from non-
invasive to CABG-capable hospitals. During the first 24
h after admission, the utilization of IV heparin, aspirin
Figure 1. Distribution of hospital types. Most hospitals in the
registry had capability to perform coronary angiography (Cath-
capable), angioplasty (PTCA-capable) or bypass surgery (CABG-
capable). CABG 5 coronary artery bypass grafting; PTCA 5
percutaneous transluminal coronary angioplasty.
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and IV nitroglycerin was higher in the more invasive
hospitals. During the entire hospitalization, coronary
arteriography was performed far more commonly in the
CABG-capable hospitals (64.9%) than either the PTCA-
capable (37.4%) or cath-capable (32.9%) hospitals (p ,
0.001). The use of pacemakers, mechanical ventilators
and intraaortic balloon pumps was also higher in the
CABG-capable hospitals, even among those patients not
having CABG, in whom the procedural frequencies were
4.2%, 9.7% and 4.6%, respectively (all p , 0.001 vs. the
less invasive hospitals).
In-hospital events. Median length of stay in the coronary
care unit was longest in the CABG-capable hospitals (3.0
vs. 2.0 days, p , 0.001) (Table 3). Total hospital stay was
also longest in CABG-capable hospitals (6.1 days overall),
partially explained by longer duration of hospitalization
among the patients undergoing CABG (median 10.7 days
vs. 5.6 days without CABG, p , 0.001) and also by the
higher proportion of patients transferred out to other
facilities among the other hospital types (noninvasive:
51.0%, cath-capable: 42.4%, PTCA-capable: 39.9% vs.
4.4% in CABG-capable, p , 0.0001). Occurring more









Number of patients 57,252 76,956 24,451 147,153
Race (% white) 91.2 88.1 87.9 83.4
Gender (% male) 60.0 59.6 60.7 62.1
Age, mean 6 SEM (yr) 68.2 6 0.06 67.7 6 0.05 67.8 6 0.09 67.0 6 .04
Payer status (%)
Commercial 19.7 21.5 21.6 22.1
HMO 7.4 7.6 8.4 10.1
Medicare 53.8 54.0 51.8 50.4
Medicaid 3.0 2.8 2.7 3.0
VA/Champus 0.5 0.6 1.1 0.7
Self/Other/Unknown 15.6 13.4 14.5 13.6
History of (%)
Diabetes 26.1 27.0 26.1 25.7
Hypertension 47.5 49.7 49.5 50.9
Angina 17.3 17.1 16.7 18.4
Prior MI 24.7 25.0 25.2 25.7
Stroke 7.7 7.7 8.3 8.1
CHF 14.8 14.4 14.4 12.9
PTCA 5.3 5.9 6.1 9.0
CABG 8.7 9.8 10.2 12.8
Admission hemodynamics
Pulse, mean 6 SEM 86.2 6 0.1 86.4 6 0.1 85.7 6 0.2 85.1 6 0.1
Systolic BP, mean
(mm Hg) 6 SEM
144.0 6 0.2 144.0 6 0.1 143.3 6 0.2 142.7 6 0.1
Admission CHF status (%)
No CHF 73.1 73.8 71.9 75.4
Rales, JVD 17.6 17.3 18.1 15.5
Pulmonary edema 7.6 7.7 8.2 7.5
Cardiogenic shock 1.7 1.3 1.8 1.7
ECG findings (%)
ST elevation—admission 45.0 43.3 44.4 44.4
Anterior/septal MI 28.0 27.4 26.8 27.9
Q-wave, MI 51.2 49.6 48.1 52.3
Risk stratification (%)
Low risk 66.1 67.9 66.6 67.1
Not low risk 32.1 30.7 31.5 31.6
Unclassified 1.8 1.4 1.9 1.4
Admission CK . twice upper
limit of normal (%)
77.7 79.8 82.5 84.6
p , 0.001 for all comparisons among Hospital Types except for Payer Status, which is not significant.
BP 5 blood pressure; CABG 5 bypass surgery; CHF 5 congestive heart failure; CK 5 creatine kinase; HMO 5 Health
Maintenance Organization; JVD 5 jugular venous distension; MI 5 myocardial infarction; PTCA 5 coronary angioplasty;
VA 5 Veterans Administration.
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frequently in the CABG-capable hospitals were stroke
(1.6%) and major bleeding (3%), both of which were more
common among the subset of patients having CABG (N 5
21,272) (stroke 2.3% vs. 1.5% and major bleeding 5.3% vs.
2.6%). Hospital mortality was similar among noninvasive,
cath-capable and PTCA-capable hospitals but was higher in
CABG-capable hospitals (Table 3) and remained higher
after adjustment for baseline covariates, including all the
variables shown in Table 1 and the U.S. census locations for
each hospital (Table 4).
Extended follow-up. Among the 30,402 patients in the
linked NRMI 2 and CCP data sets, the numbers enrolled at
noninvasive, cath-capable, PTCA-capable and CABG-
capable hospitals were 6,196; 8,089; 2,545 and 13,572, respec-
tively. In-hospital mortality was 13.7%, 13.9%, 13.4% and
15.7%, respectively (p , 0.001), but mortality at 90 days was
23.5%, 22.9%, 22.4% and 22.2%, respectively (p 5 NS).
Relative risk for 90-day mortality, adjusted for baseline covari-
ates, was also similar among the four hospital types (Table 4).
Independent predictors of 90-day mortality included age,
history of heart failure, stroke, diabetes, no prior PTCA,
admission blood pressure and pulse, evidence of heart failure
upon admission, an ECG at discharge showing anterior infarct
location or Q-waves and East South Central location.
DISCUSSION
This observational analysis from the NRMI 2 shows that a
hospital’s ability to perform coronary arteriography, PTCA
Table 2. Treatment Variables
Hospital Type
Noninvasive Cath-Capable PTCA-Capable CABG-Capable
Number of patients 57,252 76,956 24,451 147,153
Any reperfusion intervention used (%) 32.5 31.2 32.9 35.9
Physician ordering lytic therapy (%)
ED physician 51.8 52.7 58.1 60.7
Cardiologist 25.7 37.3 35.2 34.6
Primary MD 18.4 8.0 4.8 2.3
Other/unknown 4.2 2.1 1.9 2.3
Treatment time intervals, median
(75th, 25th percentiles) (h)
MI onset to door 2.17 (6.00, 1.00) 2.12 (5.83, 1.00) 2.08 (5.75, 1.00) 2.17 (5.83, 1.07)
Door to data 0.27 (1.23, 0.12) 0.27 (1.12, 0.12) 0.23 (0.92, 0.08) 0.25 (1.15, 0.10)
Data to decision 0.30 (0.62, 0.12) 0.28 (0.58, 0.12) 0.27 (0.57, 0.10) 0.28 (0.57, 0.12)
Decision to drug 0.17 (0.28, 0.08) 0.17 (0.28, 0.08) 0.17 (0.28, 0.08) 0.17 (0.28, 0.08)
Door to drug 0.75 (1.25, 0.48) 0.73 (1.25, 0.48) 0.70 (1.17, 0.45) 0.70 (1.13, 0.47)
Door to balloon — — 2.08 (3.22, 1.52) 2.20 (3.70, 1.53)
Consult before lytic therapy (%) 57.4 61.3 63.9 65.0
Medications during first 24 h (%)
IV heparin 68.5 72.2 73.6 74.6
Aspirin 73.9 74.8 77.0 77.3
IV nitroglycerin 59.0 61.9 62.0 62.7
IV beta-blocker 13.1 14.6 16.2 13.1
Oral beta-blocker 33.4 35.3 34.6 30.9
Lidocaine 15.4 14.5 14.4 15.3
Magnesium 4.4 4.4 4.4 5.4
ACE inhibitor 15.5 15.3 15.7 14.7
Calcium channel blocker 16.8 17.9 16.5 20.4
Invasive procedures (any)
Coronary arteriogram 0.0 32.9 37.4 64.9
PTCA 0.0 0.0 5.1 31.4
CABG 0.0 0.0 0.0 14.5
Other procedures
Stress test 11.5 11.4 13.1 10.7
Pacemaker 2.1 2.3 2.7 5.5
Echo 49.3 57.1 55.0 46.6
Ventilator 6.5 7.8 8.4 18.9
IABP 0.2 0.8 2.0 7.7
p , 0.001 for all comparisons among Hospital Types except for decision to drug interval (p 5 0.006) and door to balloon interval (p 5 0.03).
CABG 5 bypass surgery; IABP 5 intraaortic balloon pump; ACE 5 angiotensin converting enzyme; ED 5 emergency department; IV 5 intravenous; MD 5 physician;
MI 5 myocardial infarction; PTCA 5 coronary angioplasty.
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and CABG influences the initial management of patients
presenting with AMI. More invasively equipped hospitals
employ reperfusion therapy in a slightly higher proportion
of patients, are more prone to use primary angioplasty rather
than thrombolytic therapy and are much less apt to transfer
patients out to other facilities. However, mortality at 90
days is similar among the four hospital types.
Distribution of hospitals. The large NRMI 2 hospital
population contains a substantial representation of hospitals
both with and without invasive capability (Fig. 1). However,
in comparison with all U.S. hospitals, noninvasive hospitals
are under-represented in NRMI 2 (28.1% vs. 67.4%) in all
U.S. hospitals (2). Interestingly, in NRMI 2, noninvasive
hospitals do predominate in New England, known for its
conservative management of AMI (11).
Reperfusion interventions. In theory, hospitals with the
ability to perform immediate coronary arteriography and
mechanical revascularization might have considerable
advantage over hospitals with lesser invasive capability in
attempting reperfusion for AMI, because they could offer
primary PTCA to patients with contraindications to
thrombolytic therapy. Surprisingly, the NRMI 2 data
show that the rates of attempting reperfusion are only
marginally higher in the CABG-capable hospitals
(35.9%) than in those with lesser invasive capabilities
(range 31.2% to 32.9%). Intravenous thrombolytic ther-
apy is the most commonly employed reperfusion modality
Figure 2. Type of acute reperfusion used in the different types of
hospitals. Intravenous thrombolytic therapy was the most common
reperfusion modality employed, even in hospitals equipped to
perform invasive procedures such as IC lytic therapy, PTCA or
CABG. CABG 5 coronary artery bypass grafting; IC lytic 5
intracoronary administration of thrombolytic; IV lytic 5 intrave-
nous thrombolytic therapy; PTCA 5 percutaneous transluminal
coronary angioplasty. Unshaded area 5 IV lytic; Shaded area 5
invasive: primary PTCA, immediate CABG or IC lytic.
Table 3. In-hospital Events
Hospital Type
Noninvasive Cath-Capable PTCA-Capable CABG-Capable
Number of patients 57,252 76,956 24,451 147,153
Duration of stay, median (75th, 25th
percentiles) (days)
In coronary care unit 2.00 (3.00, 1.00) 2.00 (4.00, 1.00) 2.00 (3.00, 1.00) 3.00 (4.00, 1.00)
In-hospital
All patients 4.00 (6.63, 1.65) 4.95 (7.32, 2.70) 4.79 (7.11, 2.68) 6.08 (9.13, 4.15)
CABG patients — — — 10.67 (14.20, 7.97)
Non-CABG patients 4.00 (6.63, 1.65) 4.95 (7.32, 2.70) 4.79 (7.11, 2.68) 5.65 (8.00, 3.94)
Recurrent ischemia, % 14.0 13.1 14.6 12.3
Reinfarction, % 2.4 2.4 2.6 2.7
CHF, % 15.8 16.5 18.7 17.6
Cardiogenic shock, % 4.3 4.4 4.7 6.1
Stroke, %
All patients 0.8 1.0 0.8 1.6
CABG patients — — — 2.3
Non-CABG patients 0.8 1.0 0.8 1.5
Major bleeding, %
All patients 1.0 1.2 1.3 3.0
CABG patients — — — 5.3
Non-CABG patients 1.0 1.0 1.3 2.6
Hospital death, %
All patients 10.2 10.4 10.0 11.3
CABG patients — — — 6.7
Non-CABG patients 10.2 10.4 10.0 12.1
p , 0.001 for all comparisons among Hospital Types.
CABG 5 bypass surgery; CHF 5 congestive heart failure; PTCA 5 coronary angioplasty.
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in all categories of hospitals (Fig. 2). These data are consistent
with the notion that primary PTCA is usually employed in
patients who are also thrombolytic candidates, rather than in
patients who have exclusions for thrombolytic therapy (12).
Primary PTCA is used three to four times more commonly at
hospitals with CABG-capability than at those without
CABG-capability, likely reflecting adherence to previous
guidelines recommending that backup CABG be present
whenever acute PTCA is attempted (13).
Emergency department practices differed somewhat
among hospital types. Interphysician consultation before
administering thrombolytic therapy, a process known to
increase door-to-drug time and hospital mortality (14),
occurred in the majority of all hospital types with a
prevalence ranging from 57% in the noninvasive hospitals to
65% in the CABG-capable hospitals. The time intervals
from hospital presentation to administration of thrombo-
lytic therapy were remarkably similar among the four















Cath-capable vs. noninvasive 1.03 (0.99–1.08) 0.162 0.99 (0.92–1.06) 0.723
PTCA-capable vs. noninvasive 0.97 (0.91–1.03) 0.255 0.92 (0.83–1.01) 0.091
CABG-capable vs. noninvasive 1.14 (1.09–1.20) 0.0001 0.95 (0.89–1.02) 0.162
Bed size: 150–250 (vs. , 150) 1.07 (1.02–1.13) 0.003
Bed size: 250–350 (vs. , 150) 1.10 (1.04–1.15) 0.0003
Bed size: .350 (vs. , 150) 1.15 (1.09–1.22) 0.0001
Age (per 10-yr increase) 1.59 (1.57–1.61) 0.0001 1.51 (1.47–1.56) 0.0001
Gender: male 0.88 (0.85–0.90) 0.0001
Race: white 1.16 (1.06–1.26) 0.001
History of hypertension 1.04 (1.10–1.06) 0.012 1.05 (1.00–1.10) 0.0499
History of diabetes 1.29 (1.25–1.32) 0.0001 1.24 (1.18–1.31) 0.0001
History of heart failure 1.30 (1.25–1.34) 0.0001 1.37 (1.29–1.45) 0.0001
History of stroke 1.48 (1.42–1.53) 0.0001 1.35 (1.26–1.44) 0.0001
History of PTCA 0.72 (0.68–0.76) 0.0001 0.75 (0.66–0.85) 0.0001
History of CABG 1.16 (1.12–1.21) 0.0001
Systolic BP (per 10 mm Hg) 0.83 (0.83–0.84) 0.0001 0.88 (0.87–0.88) 0.0001
Pulse (per 10 beat increase) 1.08 (1.07–1.08) 0.0001 1.05 (1.04–1.06) 0.0001
ST-elevation on first 12-lead ECG 0.49 (0.46–0.53) 0.0001
Anterior MI location on ECG 1.19 (1.16–1.23) 0.0001 1.17 (1.10–1.23) 0.0001
Q-wave MI on ECG 1.99 (1.93–2.06) 0.0001 1.49 (1.41–1.57) 0.0001
Not low risk (vs. low risk) 1.90 (1.76–2.05) 0.0001
Unclassified risk (vs. low risk) 1.41 (1.27–1.56) 0.0001
Rales or JVD (vs. no CHF) 1.56 (1.52–1.62) 0.0001 1.64 (1.54–1.74) 0.0001
Pulmonary edema (vs. no CHF) 1.90 (1.82–1.98) 0.0001 1.87 (1.73–2.02) 0.0001
Cardiogenic shock (vs. no CHF) 8.09 (7.52–8.70) 0.0001 4.55 (4.06–5.08) 0.0001
Mid-Atlantic (vs. New England) 1.19 (1.12–1.28) 0.0001 1.06 (0.93–1.21) 0.353
South Atlantic (vs. New England) 1.28 (1.20–1.37) 0.0001 1.14 (0.099–1.30) 0.061
East North Central (vs. New England) 1.22 (1.15–1.31) 0.0001 1.13 (0.99–1.29) 0.067
East South Central (vs. New England) 1.26 (1.16–1.37) 0.0001 1.33 (1.12–1.57) 0.001
West North Central (vs. New England) 1.26 (1.16–1.36) 0.0001 1.17 (0.97–1.40) 0.094
West South Central (vs. New England) 1.40 (1.29–1.52) 0.0001 1.15 (0.98–1.35) 0.085
Mountain (vs. New England) 1.27 (1.17–1.37) 0.0001 1.06 (0.89–1.27) 0.489
Pacific (vs. New England) 1.12 (1.04–1.20) 0.002 1.13 (0.98–1.29) 0.092
Commercial/PPO (vs. HMO) 0.97 (0.90–1.04) 0.372
Medicare (vs. HMO) 1.47 (1.38–1.56) 0.0001
Medicaid (vs. HMO) 1.60 (1.44–1.77) 0.0001
VA/CHAMPUS (vs. HMO) 1.20 (0.98–1.48) 0.077
Self pay (vs. HMO) 1.40 (1.27–1.55) 0.0001
Other/Unknown payer (vs. HMO) 1.35 (1.26–1.46) 0.0001
Shown are logistic regression derived estimates of the relative risk for in-hospital mortality and Cox-regression derived estimates of the relative risk for 90-day mortality.
BP 5 blood pressure; CCP 5 Cooperative Cardiovascular Project; CHF 5 congestive heart failure; HMO 5 Health Maintenance Organization; JVD 5 jugular venous
distension; MI 5 myocardial infarction; NMRI 5 National Registry of Myocardial Infarction; PPO 5 Preferred Provider Organization.
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hospital types. We anticipated that hospitals with PTCA
capability might have longer thrombolytic treatment times
due to emergency department indecision about whether
primary PTCA or lytic therapy was the appropriate treat-
ment option. However, we found that median door-to-drug
time was actually shortest in the PTCA- and CABG-
capable hospitals (42 min) but still in excess of the recom-
mended goal of 30 min (5).
Other interventions. Other medications known to im-
prove survival of AMI when administered within the first
24 h include aspirin, beta-adrenergic blocking agents and
ACE inhibitors (15,16). Although there were minor differ-
ences in the use of these therapies among the hospital types,
the magnitude of difference was probably not clinically
important. More striking were differences in the use of
invasive procedures during hospitalization. Coronary arte-
riography was employed only about half as commonly as
cath-capable and PTCA-capable hospitals as it was at
CABG-capable hospitals (33%, 37% and 65%, respectively).
Furthermore, the frequency of performing PTCA during
hospitalization was only 5.1% at PTCA-capable hospitals
versus 31% at CABG-capable hospitals. These differences
in the use of invasive procedures may relate to a preference
for performing sequential or combined coronary arteriogra-
phy and PTCA at hospitals with CABG backup.
Outcome. We found that in-hospital mortality rates are
similar among noninvasive, Cath-capable and PTCA-
capable hospitals but higher in CABG-capable hospitals
after adjustment for baseline covariates. However, adjusted
90-day mortality rates were similar in the subset of 30,402
NRMI 2 patients who had extended follow-up in the
HCFA CCP database. The relatively higher in-hospital
mortality rates among patients initially admitted to the
CABG-capable hospitals was likely related to a combina-
tion of factors, including their longer duration of hospital-
ization, their lower likelihood of being transferred out and
the small, but finite, risk of the invasive procedures being
performed. The similar 90-day mortality among the four
hospital types is consistent with findings from randomized
trials comparing acute invasive with conservative manage-
ment post-MI. These trials uniformly failed to show an
advantage of the routine invasive approach (17–20).
Our data are also consistent with previous reports show-
ing equally good outcome for patients with AMI cared for
at community hospitals rather than at tertiary care hospitals,
despite greater utilization of invasive procedures at the latter
(21,22). Furthermore, the data support the current policy of
initially treating patients with AMI at the closest medical
facility, rather than routing them to regional centers with
specialized facilities, as is the case for trauma victims.
Patients with evidence of continuing ischemia or hemody-
namic instability can be transferred from noninvasive to
invasive facilities for specialized treatment, according to
preestablished interhospital pathways.
Study limitations. Limitations of the NRMI have previ-
ously been presented (3). The Registry does not include all
U.S. hospitals and is not a random sample of all U.S.
hospitals. There is the potential for nonconsecutive patient
enrollment, and there is no independent on-site verification
of the accuracy of registry data. Conversely, over one-fourth
of all U.S. acute care hospitals participate in NRMI 2, and
it has grown to be the largest voluntary registry of patients
with MI in the world. Hospitals collect registry data
primarily to assess the quality of their local practice patterns
for MI care, so there is great incentive to accurately record
data on consecutive patients. A recent study has shown very
high agreement between data collected independently by
NRMI 2 coordinators and data collected independently by
chart abstractors for the CCP in Medicare-eligible patients
at hospitals participating in both studies (10). Finally,
NRMI does not collect follow-up data following hospital
discharge. Data presented on survival at 90 days for the
subset of patients enrolled in both NRMI and the CCP may
not be representative of all NRMI 2 patients since the CCP
targeted an older population. Furthermore, 90-day survival
data may not be sufficient to detect an advantage, if it exists,
of invasive over conservative therapy.
Clinical implications. Within the limitations of this ob-
servational analysis, patients with AMI would appear to
receive equivalent immediate care at U.S. hospitals partici-
pating in NRMI 2, regardless of the invasive cardiac
capability of the hospitals. Although hospitals with invasive
capabilities have more options for initial reperfusion, the
proportion of patients receiving an initial reperfusion inter-
vention is only minimally greater than it is in hospitals
without invasive capabilities. Mortality rates at 90 days
follow-up, adjusted for baseline differences, are similar
among patients admitted to the four types of hospitals.
These data support the present policy of caring for patients
with AMI at the closest hospital, rather than routinely and
emergently transporting them to regional invasive revascu-
larization centers.
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